Anti Dyslipidemic Flashcards
Anti-Dyslipidemic agents are drugs used to treat __________________ in the body
dysregulations in the Lipid levels
Lipids are (organic or inorganic ?) compounds that are ________ in water but _____ in organic solvents
Organic
poorly soluble
miscible
Lipids are (soluble or insoluble?) in blood
Insoluble
TRANSPORT of Lipids
Lipids are bound to _______ in blood an transported as complexes called _______
plasma proteins
LIPOPROTEINS
LIPOPROTEIN = _____ + ________
LIPIDS + APOLIPOPROTEIN
The main classes of lipoprotein includes
?????
CHYLOMICRONS.
VERY LOW-DENSITY LIPOPROTEIN (VLDL) LOW-DENSITY LIPOPROTEIN (LDL) HIGH-DENSITY LIPOPROTEIN (HDL)
Mention the apolipoproteins they have
Chylomicrons- _________
VLDL-_________
LDL-__________
HDL-__________
A1, A4, A5, B-48
B100, C, E
B100
A1,A2, E
CHYLOMICRONS
Formed ___GENOUSLY from ______
EXO
DIETARY sources
CHYLOMICRONS
Contains mainly _________
Transport them from the ____ to the ___ for ____
TRIGLYCERIDES
G.I
TISSUES; STORAGE
VLDL –
Formed ____genously in the ____
Endo
liver
VLDL –
Contains ______________
Transports its contents from the _____ to the _____ for _______
both TRIGLYCERIDE and
CHOLESTEROL
LIVER; TISSUES; STORAGE
LDL-
Formed _____GENOUSLY through ____________
ENDO
the breakdown of VLDL
LDL-
Contains _________
Transports it from the ____ to the _____ for _____
only CHOLESTEROL
LIVER
TISSUES
STORAGE
HDL
Formed ___GENOUSLY in ______
ENDO
the TISSUES
HDL
Contains _________
Transports them from _______ to ________ for _________
only CHOLESTEROL
the TISSUE; the LIVER
EXCRETION
Dyslipidemias means presence of a ___________ in the body
deranged Lipoprotein levels
DYSLIPIDEMIA
is characterized by the combination of
( low or high?) LDL-(Cholesterol or triglyceride?)
( low or high?) VLDL - (Cholesterol or triglyceride?)
( low or high?) HDL - (Cholesterol or triglyceride?)
High; Cholesterol
High; Triglyceride
Low; Cholesterol
AETIOLOGY of DYSLIPIDEMIAs
PRIMARY DISORDERS
_____________ disease
Includes
????
Inherited
TYPE I TYPE IIa TYPE IIb TYPE III TYPE IV TYPE V
AETIOLOGY of DYSLIPIDEMIAs
SECONDARY DISORDERS
Diabetes mellitus
Obesity
Alcoholism
Nephrotic syndrome Chronic renal failure Liver disease Hypothyroidism Drugs
You understand 🍻
DYSLIPIDEMIA: CLINICAL FEATURES
______ological
_______ological
____________
Dermat
Ophthalm
Gastrointestinal
DYSLIPIDEMIA: CLINICAL FEATURES
Dermatological
————-
__________
___________
Xanthomas
Xanthelasmas
Xanthomata
DYSLIPIDEMIA: CLINICAL FEATURES
Ophthalmological
_______
__________/______
Lipemia retinalis
Arcus lipoides cornea/ arcus senilis
DYSLIPIDEMIA: CLINICAL FEATURES
Gastrointestinal
________ or _______
Fatty Liver or Hepatic Steatosis
COMPLICATIONS of DYSLIPIDEMIA
State which is attributed to cholesterol and which is to triglycerides
Atherosclerosis
Angina pectoris
Myocardial infarction
cholesterol
cholesterol
cholesterol
COMPLICATIONS of DYSLIPIDEMIA
State which is attributed to cholesterol and which is to triglycerides
Ischemic cerebrovascular disease/ Stroke Peripheral vascular disease
Pancreatitis
cholesterol
triglycerides
DIAGNOSIS of DYSLIPIDEMIA
Lipid Profile:
_______
_________
_________
___________
Total Cholesterol
LDL Cholesterol
HDL Cholesterol
Triglyceride
Target cholesterol levels
Total cholesterol - less than ______mg/dL
LDL - less than ______mg/dL
HDL- _____ mg /dL or higher
Triglycerides-less than ______mg/dL
200
100
60
150
Non-Pharmacological TREATMENT of DYSLIPIDEMIA
_____ modification
________
________ restriction
Dietary
Exercise
Alcohol
Non-Pharmacological TREATMENT of DYSLIPIDEMIA
Dietary modification such as _______ , _____,——— etc
Low calories
Low saturated fats
High fiber
Anti-Dyslipidemic agents
Includes
_________
_________
_________
_________
_________
_________
STATINS
FIBRATES
NIACIN
BILE ACID RESIN EZETIMIBE
FISH OIL DERIVATIVES.
STATIN
EXAMPLES
???
Simvastatin
Lovastatin
Pravastatin
Fluvastatin
Rosuvastatin
Atovastatin
MECHANISM OF ACTION of STATIN
Inhibit the _________ of _______ in the ____
endogenous synthesis ; cholesterol; Liver
MECHANISM OF ACTION of STATIN
Bind and block ________________________ in the _____ pathway.
3-HYDROXY-3- METHYLGLUTARYL COENZYME A (HMG- COA) REDUCTASE
Cholesterol